TELA

TELA Bio, Inc.

$0.80

-7.47%
SectorHealthcareIndustryMedical DevicesCountryUnited States

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Source: Yahoo Finance
AI summary

Price & performance

1M-7.3%
3M+28.7%
YTD-11.4%
1Y-31.8%
52-week range—
Beta0.82
Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth42
Risk44
Performance32
Valuation43
Profitability51
Leverage38
Sentiment35
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$80.3M+15.8%
Net income-$38.8M
Net margin-48.4%+6.2 pts
Historical fundamentals

Red flags in filings

1active red flag
Exchange listing noticeSep 18, 2026
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

TELAIndustryP/E—29.61P/S0.453.49EV/EBITDA—18.38P/B—3.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 10next report, after the close
EPS estimate$-0.15
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate